Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 6, 2002, Pages 513-518

  Blann, A D ^a   McCollum, C N ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Framingham; Hypercholesterolaemia; Hypertension; Smoking; Soluble E selectin; Soluble thrombomodulin; Von Willebrand factor

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; THROMBOMODULIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LABORATORY DIAGNOSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SMOKING; BIOLOGICAL MODEL; BLOOD; CARDIOVASCULAR DISEASE; COMPUTER PROGRAM; CYTOLOGY; METABOLISM; MIDDLE AGED; VASCULAR ENDOTHELIUM;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; RISK FACTORS; SOFTWARE; THROMBOMODULIN; VON WILLEBRAND FACTOR;

EID: 0036743074     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200209000-00006     Document Type: Article

References (42)

1. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
3. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995; 90: 244-248.
4. Lip GYH, Blann AD. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34: 255-265.
5. Davi G, Romano M, Mezzetti A, Procopio A, Iacobelli S, Antidormi T, et al. Increased levels of soluble P-selectin in hypercholesterolaemic patients. Circulation 1998; 97: 953-957.
6. Blann AD, McCollum CN. Adverse influence of cigarette smoking on the endothelium. Thromb Haemost 1993; 70: 707-711.
7. Kloczko J, Wojtukiewicz MZ, Bielawiec M, Galar M, Tarasow E. von Willebrand factor antigen and fibronectin in essential hypertension. Thromb Res 1995; 79: 331-336.
8. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, et al., for the ECAT group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641.
9. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease. Circulation 1997; 96: 1102-1108.
10. Boffa MC. Considering cellular thrombomodulin distribution and its modulating factors can facilitate the use of plasma thrombomodulin as a reliable endothelial marker. Haemostasis 1996; 26 (suppl 4): 233-243.
11. Seigneur M, Dufourcq P, Conri C, Constans J, Mercie P, Pruvost A, et al. Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thromb Res 1993; 71: 423-431.
12. Jansson JH, Boman K, Brannstrom M, Nilsson TK. Increased levels of plasma thrombomodulin are associated with vascular and all-cause mortality in patients on long term anticoagulant treatment. Eur Heart J 1996; 17: 1503-1505.
13. Blann AD, Steele C, McCollum CN. Influence of smoking on soluble adhesion molecules and endothelial cell markers. Thromb Res 1997; 85: 433-438.
14. Amiral J. Usefulness of laboratory techniques for evaluating antithrombotic efficacy of new therapeutic strategies. Clin Appl Thromb/Haemost 1995; 1: 243-259.
15. Cacoub P, Karmochkine M, Dorent R, Nataf P, Piette JC, Godeau P, et al. Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med 1996; 101: 160-164.
16. Smith CW. Potential significance of circulating E-selectin. Circulation 1997; 95: 1986-1988.
17. Newman W, Beall LD, Carson CW, Hunder GG, Graben N, Randhawa ZI, et al. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 1993; 150: 644-654.
18. Belch JJF, Shaw JW, Kirk G, et al. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty. Circulation 1997; 95: 2027-2031.
19. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation 1997; 96: 4219-4225.
20. Sampietro T, Tuoni M, Ferdeghini M, Ciardi A, Marraccini P, Prontera C, et al. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolaemia. Circulation 1997; 96: 1381-1385.
21. Buemi M, Allegra A, Aloisi C, Corica F, Alonci A, Ruello A, et al. Cold pressor test raises serum concentrations of ICAM-1, VCAM-1 and E-selectin in normotensive and hypertensive patients. Hypertension 1997; 30: 845-847.
22. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362 (see also www.nhli.nih.gov/about/framingham/riskabs.htm).
23. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1990; 121: 293-298.
24. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Org 1962; 27: 645-658.
25. Machin D, Campbell M. Statistical tables for the design of clinical trials. Oxford: Blackwell Scientific; 1987.
26. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsum AR, Juneja H, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999; 353: 1729-1734.
27. Conlan MG, Folsum AR, Funch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. Thromb Haemost 1993; 70: 380-385.
28. Markuljak I, Ivankova J, Kubisz P. Thrombomodulin and von Willebrand factor in smokers and during smoking. Nouv Rev Fr Hematol 1995; 37: 137-139.
29. Folsum AR, Conlan MG, Davis CE, Wu KK. Relationships between hemostatic variables and cardiovascular risk factors in middle-aged adults. Ann Epidemiol 1992; 2: 481-494.
30. Blann AD, Lip GYH. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 (insulin dependent) diabetes mellitus. Diabetic Med 1998; 15: 634-642.
31. D'Agostino RB, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores. JAMA 2001; 286: 180-187.
32. Blann AD, T Naqvi, M Waite, CN McCollum. von Willebrand factor and endothelial cell damage in essential hypertension. J Hum Hypertens 1993; 7: 107-111.
33. Stott DJ, Spilig E, Campbell AM, Rumley A, Mansoor MA, Lowe GDO. Haemostasis in ischaemic stroke and vascular dementia. Blood Coagul Fibrinolysis 2001; 12: 651-657.
34. Van Den Berg M, Boers GHJ, Franken DG, Blom HJ, van Kamp GJ, Jakobs C, et al. Hyperhomocysteinaemia and endothelial cell dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176-181.
35. Demerath E, Towne B, Blangero J, Siervogel RM. The relationship of soluble ICAM-1, VCAM-1, P-selectin and E-selectin to cardiovascular disease risk factors in healthy men and women. Annals Hum Biol 2001; 28: 664-678.
36. Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001; 358: 971-975.
37. Booth F, Allington MJ, Cederholm-Williams SA. An in vitro method for the study of acute release of von Willebrand factor from human endothelial cells. Br J Haematol 1987; 67: 71-78.
38. Penny WF, Weinstein M, Slazman EW, Ware JA. Correlation of circulating von Willebrand factor levels with cardiovascular haemodynamics. Circulation 1991; 83: 1630-1636.
39. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, et al. Correlation between oxidised low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 1996; 76: 663-669.
40. 2-isoprostanes) in smokers. N Engl J Med 1995; 332: 1198-1203.
41. Smith FB, Lee AJ, Hau CM, Rumley A, Lowe GDO, Fowkes FGR. Plasma fibrinogen, haemostatic factors and prediction of peripheral arterial disease in the Edinburgh Artery Study. Blood Coagul Fibrinolysis 2000; 11: 43-50.
42. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communitties (ARC) study. Ann Int Med 2000; 133: 81-91.